Literature DB >> 14766749

Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.

Kieron Brown1, Joanna M Long, Sarah C M Vial, Neesha Dedi, Nicholas J Dunster, Suzanne B Renwick, Adam J Tanner, J Dan Frantz, Mark A Fleming, Graham M T Cheetham.   

Abstract

Interleukin-2 tyrosine kinase, Itk, is an important member of the Tec family of non-receptor tyrosine kinases that play a central role in signaling through antigen receptors such as the T-cell receptor, B-cell receptor, and Fcepsilon. Selective inhibition of Itk may be an important way of modulating many diseases involving heightened or inappropriate activation of the immune system. In addition to an unliganded nonphophorylated Itk catalytic kinase domain, we determined the crystal structures of the phosphorylated and nonphosphorylated kinase domain bound to staurosporine, a potent broad-spectrum kinase inhibitor. These structures are useful for the design of novel, highly potent and selective Itk inhibitors and provide insight into the influence of inhibitor binding and phosphorylation on the conformation of Itk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766749     DOI: 10.1074/jbc.M400031200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Disrupting the intermolecular self-association of Itk enhances T cell signaling.

Authors:  Lie Min; Wenfang Wu; Raji E Joseph; D Bruce Fulton; Leslie Berg; Amy H Andreotti
Journal:  J Immunol       Date:  2010-03-17       Impact factor: 5.422

2.  Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.

Authors:  Wenchang Guo; Ruiwu Liu; Yoko Ono; Ai-Hong Ma; Anthony Martinez; Eduardo Sanchez; Yan Wang; Wenzhe Huang; Anisha Mazloom; Jixian Li; Jinying Ning; Emanual Maverakis; Kit S Lam; Hsing-Jien Kung
Journal:  Mol Pharmacol       Date:  2012-08-16       Impact factor: 4.436

3.  Controlling the activity of the Tec kinase Itk by mutation of the phenylalanine gatekeeper residue.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Biochemistry       Date:  2010-12-16       Impact factor: 3.162

4.  Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.

Authors:  Chandrasekaran Meganathan; Sugunadevi Sakkiah; Yuno Lee; Jayavelu Venkat Narayanan; Keun Woo Lee
Journal:  J Mol Model       Date:  2012-09-27       Impact factor: 1.810

5.  Identification of an allosteric signaling network within Tec family kinases.

Authors:  Raji E Joseph; Qian Xie; Amy H Andreotti
Journal:  J Mol Biol       Date:  2010-09-06       Impact factor: 5.469

6.  Conformational snapshots of Tec kinases during signaling.

Authors:  Raji E Joseph; Amy H Andreotti
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.

Authors:  Douglas J Marcotte; Yu-Ting Liu; Robert M Arduini; Catherine A Hession; Konrad Miatkowski; Craig P Wildes; Patrick F Cullen; Victor Hong; Brian T Hopkins; Elisabeth Mertsching; Tracy J Jenkins; Michael J Romanowski; Darren P Baker; Laura F Silvian
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

8.  Characterization of a novel interaction between transcription factor TFII-I and the inducible tyrosine kinase in T cells.

Authors:  Catarina Sacristán; Stefan A Schattgen; Leslie J Berg; Stephen C Bunnell; Ananda L Roy; Yvonne Rosenstein
Journal:  Eur J Immunol       Date:  2009-09       Impact factor: 5.532

9.  Mechanism and functional significance of Itk autophosphorylation.

Authors:  Raji E Joseph; D Bruce Fulton; Amy H Andreotti
Journal:  J Mol Biol       Date:  2007-08-31       Impact factor: 5.469

Review 10.  ITK inhibitors in inflammation and immune-mediated disorders.

Authors:  Nisebita Sahu; Avery August
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.